Uterine myomectomy

Free From Fibroids Will Raise Awareness of all Available Treatment Options for Symptomatic Uterine Fibroids

Retrieved on:

Wednesday, June 30, 2021

Gynaecological neoplasia, Uterine fibroid, Clinical medicine, Medicine, Health, Gynecological surgery, Surgical instruments, Uterine myomectomy, Uterine artery embolization

WASHINGTON , June 30, 2021 /PRNewswire-PRWeb/ -- Today, Free From Fibroids and the Fibroid Coalition officially launched their efforts to raise awareness of all available treatment options for uterine fibroids.

Key Points:

WASHINGTON , June 30, 2021 /PRNewswire-PRWeb/ -- Today, Free From Fibroids and the Fibroid Coalition officially launched their efforts to raise awareness of all available treatment options for uterine fibroids.
They have assembled a group of individuals who are passionate about providing patients and physicians with non-surgical treatment options for fibroids.
Uterine fibroids are diagnosed roughly three times more frequently in Black women and women of color than in white women of the same age.
Free From Fibroids is dedicated to the following:
To support and empower women suffering with uterine fibroids.

Worldwide Myomectomy Industry to 2026 - Rise in Minimally Invasive Procedures is Driving Growth - ResearchAndMarkets.com

Retrieved on:

Monday, June 21, 2021

Surgery, Health, Gynecological surgery, Clinical medicine, Medicine, Gynaecological neoplasia, Uterine fibroid, Uterine myomectomy, Medical specialties, Surgical instruments, Morcellator, Victor Bonney

According to this, myomectomy procedures were classified under surgeries that can be delayed by several months.

Key Points:

According to this, myomectomy procedures were classified under surgeries that can be delayed by several months.
These guidelines resulted in surgeons delaying myomectomy procedures which will impact devices used in the myomectomy market.
With the rise in patients with uterine fibroids, the demand for myomectomy procedures will also increase.
These factors along with high reimbursement rates and government initiatives contribute to North America occupying the largest share within the Myomectomy market.

Gynesonics Announces Positive Payer Coverage Issued by Blue Cross Blue Shield of Florida (Florida Blue) for the Sonata Treatment

Retrieved on:

Thursday, June 10, 2021

The Sonata Treatment is a breakthrough alternative to hysterectomy and myomectomy, and can treat a wide range of fibroid types, sizes, and locations.

Key Points:

The Sonata Treatment is a breakthrough alternative to hysterectomy and myomectomy, and can treat a wide range of fibroid types, sizes, and locations.
Fibroids are treated from inside the uterus, so the Sonata Treatment requires no incisions, no tissue is surgically removed, and the uterus is preserved.
This is a great decision by Florida Blue that recognizes the importance of offering this minimally invasive option to women.
They are recognizing the clinical efficacy of the Sonata Procedure and as a result are creating access to a less invasive treatment option with the Sonata System.

New Fibroid Management Guidance from the American College of Obstetricians and Gynecologists Supports Laparoscopic Radiofrequency Ablation (Lap-RFA) as a Minimally Invasive, Uterine Preserving Treatment Option

Retrieved on:

Monday, May 24, 2021

Health, Medical devices, Consumer, Women, Surgery, General Health, Radiology, Medicine, Clinical medicine, Medical specialties, Interventional radiology, Surgical oncology, Gynaecological neoplasia, Uterine fibroid, Radiofrequency ablation, Ablation, Uterine artery embolization, Uterine myomectomy

Hologic, Inc. (Nasdaq: HOLX), a global leader in womens health, announced today that the American College of Obstetricians and Gynecologists (ACOG), in its updated guidance for Management of Symptomatic Uterine Leiomyomas , supports the use of laparoscopic radiofrequency ablation (Lap-RFA) for the treatment of uterine fibroids.

Key Points:

Hologic, Inc. (Nasdaq: HOLX), a global leader in womens health, announced today that the American College of Obstetricians and Gynecologists (ACOG), in its updated guidance for Management of Symptomatic Uterine Leiomyomas , supports the use of laparoscopic radiofrequency ablation (Lap-RFA) for the treatment of uterine fibroids.
ACOGs updated guidance in Practice Bulletin Number 228 will help physicians and patients considering fibroid treatment recognize Lap-RFA as a safe and effective uterine sparing option.
The Acessa procedure provides a minimally invasive, uterine-sparing surgical option for women with symptomatic fibroids who would otherwise require more invasive intervention.
This treatment combines laparoscopic ultrasound with radiofrequency ablation to destroy fibroid tissue through coagulation necrosis.

Gynesonics Announces Publication of Clinical Study Analysis Demonstrating Effectiveness of the Sonata System in Treating Submucous and Large Symptomatic Uterine Fibroids

Retrieved on:

Thursday, April 8, 2021

Health, Medical devices, Consumer, Women, Surgery, General Health, Clinical trials, Clinical medicine, Medicine, Neoplasms, Gynaecological neoplasia, Uterine fibroid, Gynecological surgery, Uterine myomectomy, Surgical oncology, Interventional radiology, Heavy menstrual bleeding, Sonata System, Gynesonics

Among 197 women (with 534 treated fibroids), 86% of patients with only submucous fibroids and 81% of women with large fibroids (>5 cm) experienced bleeding reduction within 3 months post-ablation.

Key Points:

Among 197 women (with 534 treated fibroids), 86% of patients with only submucous fibroids and 81% of women with large fibroids (>5 cm) experienced bleeding reduction within 3 months post-ablation.
Additional fibroid mapping of large fibroids with magnetic resonance imaging in the FAST-EU trial showed an average volume reduction of 68%.
Transcervical fibroid ablation with the Sonata system for treatment of submucous and large uterine fibroids.
Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.

Gynesonics Announces Positive Payer Coverage Issued by Health Care Service Corporation (HCSC) for the Sonata Treatment

Retrieved on:

Monday, March 15, 2021

Gynesonics, a womens healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Health Care Service Corporation (HCSC) has released a coverage policy for The Sonata Procedure.

Key Points:

Gynesonics, a womens healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Health Care Service Corporation (HCSC) has released a coverage policy for The Sonata Procedure.
The Sonata Treatment is a breakthrough alternative to hysterectomy and myomectomy, and can treat a wide range of fibroid types, sizes, and locations.
Fibroids are treated from inside the uterus, so the Sonata Treatment requires no incisions, no tissue is surgically removed, and the uterus is preserved.
Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.

Sonata, a New Innovative, Incision-Free Procedure to Treat Symptomatic Uterine Fibroids, Expands in New York Area

Retrieved on:

Tuesday, October 27, 2020

Health, Medical devices, Consumer, Hospitals, Women, Surgery, Radiology, Benign neoplasms, Anatomy, Gynaecology, Gynaecological neoplasia, Uterine fibroid, Clinical medicine, Uterus, Uterine myomectomy, Heavy menstrual bleeding, Sonata System, Gynesonics

Symptoms may worsen over time if fibroids are left untreated, which leads to more than two million women in the U.S. undergoing treatment for uterine fibroids each year.

Key Points:

Symptoms may worsen over time if fibroids are left untreated, which leads to more than two million women in the U.S. undergoing treatment for uterine fibroids each year.
NewYork-Presbyterian Lawrence Hospital in Bronxville, N.Y., where the procedure is performed, began using the Sonata System in July.
We can now offer a new advanced gynecologic treatment option for some women with symptomatic uterine fibroids that is incision-free, fast and can be particularly beneficial during childbearing years.
Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.

Myomectomy Market Size Worth USD 1.1 Billion By 2027 | CAGR 9.1%: Grand View Research, Inc.

Retrieved on:

Tuesday, September 15, 2020

Medicine, Clinical medicine, Medical specialties, Gynecological surgery, Uterine myomectomy, Hysterectomy, Laparoscopy, Minimally invasive procedure, Uterine fibroid

Fibroids majorly develop in 50.0% of women, which have led to increased demand for the procedure and it preserves the uterus, unlike hysterectomy.

Key Points:

Fibroids majorly develop in 50.0% of women, which have led to increased demand for the procedure and it preserves the uterus, unlike hysterectomy.
Nowadays, minimally invasive treatment options for the procedure include laparoscopic or robotic, and hysteroscopic myomectomy.
Furthermore, the incorporation of new technologies and the introduction of new products by market players are expected to boost market growth during the forecast period.
Grand View Research has segmented the global myomectomy market on the basis of type, product, and region:

Myomectomy Market Size Worth USD 1.1 Billion By 2027 | CAGR 9.1%: Grand View Research, Inc.

Retrieved on:

Tuesday, September 15, 2020

Medicine, Clinical medicine, Medical specialties, Gynecological surgery, Uterine myomectomy, Hysterectomy, Laparoscopy, Minimally invasive procedure, Uterine fibroid

Fibroids majorly develop in 50.0% of women, which have led to increased demand for the procedure and it preserves the uterus, unlike hysterectomy.

Key Points:

Fibroids majorly develop in 50.0% of women, which have led to increased demand for the procedure and it preserves the uterus, unlike hysterectomy.
Nowadays, minimally invasive treatment options for the procedure include laparoscopic or robotic, and hysteroscopic myomectomy.
Furthermore, the incorporation of new technologies and the introduction of new products by market players are expected to boost market growth during the forecast period.
Grand View Research has segmented the global myomectomy market on the basis of type, product, and region:

Gynesonics Announces Brigham and Women’s Faulkner Hospital Becomes The First In Massachusetts To Offer Innovative New Procedure To Treat Symptomatic Uterine Fibroids

Retrieved on:

Thursday, September 3, 2020

Medical devices, Health, Consumer, Hospitals, Women, Biotechnology, Clinical medicine, Medicine, Benign neoplasms, RTT, Gynaecological neoplasia, Uterine fibroid, Medical specialties, Uterine artery embolization, Uterine myomectomy, Brigham and Women’s Faulkner Hospital, Sonata System, Gynesonics

Gynesonics, a womens healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Brigham and Womens Faulkner Hospital is the first provider in Massachusetts to offer the Sonata System as a treatment for symptomatic uterine fibroids.

Key Points:

Gynesonics, a womens healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Brigham and Womens Faulkner Hospital is the first provider in Massachusetts to offer the Sonata System as a treatment for symptomatic uterine fibroids.
Symptoms may worsen over time if fibroids are left untreated, which leads to more than two million women in the U.S. undergoing treatment for uterine fibroids each year.
For the first time, the Sonata System allows us to provide women a completely incision-free procedure to treat single or multiple fibroids, with very fast recovery and excellent results.
Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.